Bring the immune system one step ahead of cancer

Unlocking the full potential of immuno-oncology by generating first-in-class immunotherapies to initiate a multi-specific in vivo immune response against tumors

THEY SUPPORT US

Inspired by patients, driven by science

At Brenus Pharma, we develop a new generation of treatments that will overcome limitations of classical immunotherapies and cell therapies— poor efficacy on cold tumors, manufacturing cost and supply issues— and improve the patient’s access to innovation

Solid tumors

Fast growing needs, insufficient solutions

of patient face  therapeutic failure

0 %

leading to

every year worldwide

0 M deaths

The challenge

Cancer is a moving, heterogeneous & invisible target

Example of colorectal cancer (CRC): a cold tumor defined by heterogeneity, plasticity and treatment resistances

95% of patients (MSS type) have no other solution than outdated chemotherapies

5-year survival < 12%
2nd leading cause of cancer mortality worldwide

For these patients: the immune system, natural body’s defenser, is blinded

New therapeutic strategies are needed to restore anti-tumor immune response and capture cancer heterogeneity

Our solution: 
Stimulated tumor Ghost Cells (SGC) technology

From “off-the-shelf” tumor banks to first-in-class immunotherapies

Enriched with the molecular fingerprints of tumor heterogeneity and resistances, non proliferative and safely immunogenic

Designed to unlock in vivo the immune system to fight back

1. Mimicking cancer plasticity with stimulated « off-the-shelf » tumor cell lines

Allogeneic cell lines selected to cover wide patient populations of the targeted indication

Stimulation by standards of care and physical shock to reveal + 200 cancer related proteins (CRP), linked to tumor specificity, plasticity and resistances mechanisms validated by proteogenomic and predictive model

2. Making it visible

Safely engage the immune system with haptenation and inactivation process (Ghost cell), enhancing recognition of proteins by Antigen Presenting Cells (APCs) at in vivo level